Literature DB >> 22205851

A case of minimal change disease treated successfully with mycophenolate mofetil in a patient with systemic lupus erythematosus.

Young Hoon Hong1, Dae Young Yun, Yong Wook Jung, Myung Jin Oh, Hyun Je Kim, Choong Ki Lee.   

Abstract

The World Health Organization classifies lupus nephritis as class I to V or VI. However, a few cases of minimal change glomerulopathy have been reported in association with systemic lupus erythematosus (SLE). Mycophenolate mofetil has been shown to be effective for treatment of minimal change disease and lupus nephritis. A 24-year-old woman diagnosed with SLE five years prior to presentation complained of a mild generalized edema. The urinalysis showed microscopic hematuria and proteinuria. The assessed amount of total proteinuria was 1,618 mg/24 hours. A renal biopsy demonstrated diffuse fusion of the foot processes of podocytes on electron microscopy. Mycophenolate mofetil was started in addition to the maintenance medications of prednisolone 10 mg/day and hydroxychloroquine 400 mg/day. After six months of treatment, the microscopic hematuria and proteinuria resolved, and the total urine protein decreased to 100 mg/24 hours.

Entities:  

Keywords:  Lupus erythematosus, systemic; Mycophenolate mofetil; Nephrosis, lipoid

Mesh:

Substances:

Year:  2011        PMID: 22205851      PMCID: PMC3245399          DOI: 10.3904/kjim.2011.26.4.470

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  8 in total

1.  Minimal change disease in systemic lupus erythematosus.

Authors:  G K Dube; G S Markowitz; J Radhakrishnan; G B Appel; V D D'Agati
Journal:  Clin Nephrol       Date:  2002-02       Impact factor: 0.975

2.  Failure of mycophenolate mofetil therapy in primary refractory nephrotic syndrome.

Authors:  Veronica Baglio; Gabriella Pecci; Concetta Gangemi; Giusi Barresi; Santo Morabito; Alessandro Pierucci
Journal:  J Nephrol       Date:  2006 Nov-Dec       Impact factor: 3.902

3.  A case of minimal-change nephrotic syndrome in pediatric lupus erythematosus: just a coincidence?

Authors:  Y T Wang; H H Chou; F F Chen; M J Chen; Y Y Chiou
Journal:  Lupus       Date:  2006       Impact factor: 2.911

4.  Mycophenolate mofetil treatment for primary glomerular diseases.

Authors:  Michael J Choi; Joseph A Eustace; Luis F Gimenez; Mohamed G Atta; Paul J Scheel; Renuka Sothinathan; William A Briggs
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

5.  Minimal-change nephrotic syndrome associated with systemic lupus erythematosus.

Authors:  H Makino; T Haramoto; K Shikata; T Ogura; Z Ota
Journal:  Am J Nephrol       Date:  1995       Impact factor: 3.754

6.  Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome.

Authors:  Minghui Zhao; Xiangmei Chen; Yipu Chen; Zhangsuo Liu; Yuchun Liu; Fangping Lu; Yanping Zhang; Haiyan Wang
Journal:  Nephrology (Carlton)       Date:  2003-06       Impact factor: 2.506

7.  Glomerular podocytopathy in patients with systemic lupus erythematosus.

Authors:  Steven W Kraft; Melvin M Schwartz; Stephen M Korbet; Edmund J Lewis
Journal:  J Am Soc Nephrol       Date:  2004-11-17       Impact factor: 10.121

8.  Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy.

Authors:  Todd E Pesavento; William H Bay; Garima Agarwal; Raul A Hernandez; Lee A Hebert
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860

  8 in total
  1 in total

1.  Acute kidney injury associated with minimal change disease in systemic lupus erythematosus: a case report.

Authors:  Xin Wei; Ying Wang; Luxia Tu; Hongping Wan; Qinkai Chen
Journal:  J Med Case Rep       Date:  2014-12-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.